Literature DB >> 29039050

The protective effect of fish oil lipid emulsions on intestinal failure-associated liver disease in a rat model of short-bowel syndrome.

Seiro Machigashira1, Tatsuru Kaji1, Shun Onishi1, Waka Yamada1, Keisuke Yano1, Koji Yamada1, Ryuta Masuya1, Takafumi Kawano1, Kazuhiko Nakame1, Motoi Mukai1, Satoshi Ieiri2.   

Abstract

PURPOSE: Pediatric patients with intestinal failure need long-term parenteral nutrition (PN), but this nutritional support causes liver dysfunction, such as intestinal failure-associated liver disease (IFALD). Several studies have shown that the lipid emulsion produced by soybean oil (SO) is associated with the occurrence of IFALD. In this study, we evaluated the effect of SO and fish oil (FO) lipid emulsion on hepatic steatosis.
METHODS: Sprague-Dawley rats underwent jugular vein catheterization and were divided into three groups: sham operation with normal chow (Sham group), 80% small bowel resection (80% SBR) + TPN with SO lipid emulsion (SO group), and 80% SBR + TPN with FO lipid emulsion (FO group). All rats were euthanized and the serum biochemistry and hepatic histology analyzed.
RESULTS: No significant differences in the serum liver or biliary enzymes were noted between the SO and FO groups. The pathological findings and NAFLD score in the FO group did not show steatosis and were significantly lower than in the SO group. An analysis of the fatty acids profile in the both the SO and FO groups did not indicate essential fatty acid deficiency (EFAD).
CONCLUSION: FO lipid emulsion may have a protective role against steatosis of IFALD without EFAD.

Entities:  

Keywords:  Fish oil; Intestinal failure-associated liver disease; Short-bowel syndrome; Soy bean oil

Mesh:

Substances:

Year:  2017        PMID: 29039050     DOI: 10.1007/s00383-017-4190-4

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  19 in total

Review 1.  Parenteral fish oil monotherapy in the management of patients with parenteral nutrition-associated liver disease.

Authors:  Vincent E de Meijer; Kathleen M Gura; Jonathan A Meisel; Hau D Le; Mark Puder
Journal:  Arch Surg       Date:  2010-06

2.  1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR).

Authors:  Berthold Koletzko; Olivier Goulet; Joanne Hunt; Kathrin Krohn; Raanan Shamir
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-11       Impact factor: 2.839

Review 3.  Essential fatty acids: biochemistry, physiology and pathology.

Authors:  Undurti N Das
Journal:  Biotechnol J       Date:  2006-04       Impact factor: 4.677

4.  Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model.

Authors:  Jonathan A Meisel; Hau D Le; Vincent E de Meijer; Vania Nose; Kathleen M Gura; Robert V Mulkern; M Reza Akhavan Sharif; Mark Puder
Journal:  J Pediatr Surg       Date:  2011-04       Impact factor: 2.545

5.  Effect of sex and age on fatty acid composition of human serum lipids.

Authors:  R T Holman; L Smythe; S Johnson
Journal:  Am J Clin Nutr       Date:  1979-12       Impact factor: 7.045

6.  Effects of fat emulsions with different fatty acid composition on plasma and hepatic lipids in rats receiving total parenteral nutrition.

Authors:  W J Chen; S L Yeh; P C Huang
Journal:  Clin Nutr       Date:  1996-02       Impact factor: 7.324

Review 7.  Mechanisms for the effects of fish oil lipid emulsions in the management of parenteral nutrition-associated liver disease.

Authors:  P Nandivada; E Cowan; S J Carlson; M Chang; K M Gura; M Puder
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2013-04-18       Impact factor: 4.006

8.  Pediatric intestinal failure-associated liver disease is reversed with 6 months of intravenous fish oil.

Authors:  Kara L Calkins; James C Y Dunn; Stephen B Shew; Laurie Reyen; Douglas G Farmer; Sherin U Devaskar; Robert S Venick
Journal:  JPEN J Parenter Enteral Nutr       Date:  2013-07-26       Impact factor: 4.016

Review 9.  Safety considerations with omega-3 fatty acid therapy.

Authors:  Harold E Bays
Journal:  Am J Cardiol       Date:  2006-11-28       Impact factor: 2.778

Review 10.  A.S.P.E.N. clinical guidelines: support of pediatric patients with intestinal failure at risk of parenteral nutrition-associated liver disease.

Authors:  Paul W Wales; Nancy Allen; Patricia Worthington; Donald George; Charlene Compher; Daniel Teitelbaum
Journal:  JPEN J Parenter Enteral Nutr       Date:  2014-04-02       Impact factor: 4.016

View more
  2 in total

1.  Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome.

Authors:  Keisuke Yano; Tatsuru Kaji; Shun Onishi; Seiro Machigashira; Taichiro Nagai; Toshio Harumatsu; Koji Yamada; Waka Yamada; Mitsuru Muto; Kazuhiko Nakame; Motoi Mukai; Satoshi Ieiri
Journal:  Pediatr Surg Int       Date:  2019-09-25       Impact factor: 1.827

2.  The administration of hepatocyte growth factor prevents total parenteral nutrition-induced hepatocellular injury in a rat model.

Authors:  Makoto Matsukubo; Keisuke Yano; Tatsuru Kaji; Koshiro Sugita; Shun Onishi; Toshio Harumatsu; Ayaka Nagano; Mayu Matsui; Masakazu Murakami; Koji Yamada; Waka Yamada; Mitsuru Muto; Kotaro Kumagai; Akio Ido; Satoshi Ieiri
Journal:  Pediatr Surg Int       Date:  2021-01-03       Impact factor: 1.827

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.